Moderna, Inc., a biopharma company developing messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a developer of cell-free DNA synthesis and amplification technologies based in Japan, have entered into a definitive agreement under which Moderna will acquire OriCiro for $85 million.
“With this acquisition, we obtain best-in-class tools for cell-free synthesis and amplification of plasmid DNA, a key building block in mRNA manufacturing,” said Stéphane Bancel, Chief Executive Officer of Moderna. “OriCiro’s technology strategically complements our manufacturing expertise and further accelerates our research and development engine. We look forward to welcoming the OriCiro team to Moderna.”
